Reviewer's report

Title: Survey of Human Papillomavirus Types and Maternal-fetal Transmission in Pregnant Women

Version: 1 Date: 16 September 2012

Reviewer: Renato Luís Rombaldi

Reviewer's report:

Minor essential revisions were suggested.

Suggestions

Abstract:

Result:
- 13.4% (n=422/3139);
- HPV-16 (29.62%, n=125/422), HPV-18 (14.7%, n=62/422), and HPV-58 (14.2%, n=60/422);
- 23.6% (n=55/233);

Conclusion:
- (17.7% vs. 11.6%);
- 13.4%; remove from the text "during pregnancy";
- 23.6%;
- 46.4%;

Condensation:
- 13.4%;
- 23.6%;

Abstract

Objective
- change text in the third person. The study;

Setting and Population or Sample
- change text in the third person;

Methods
- (gestational age: 24.6±2.1 weeks);
- (<24h old);

Results
- 14.7;
- (n=422/3139);
- (29.6%, n=125/422), HPV-18 (14.7%, n=62/422), and HPV-58 (14.2%, n=60/422);
- 23.6% (n=55/233);
- (17.7% vs. 11.6%).

Conclusion
- 13.4%;
- 23.6%;
- 46.4%;

Introduction
First paragraph
- papillomatosis and anogenital warts;

Five paragraph
- change text in the third person;

Materials and methods
Participants
first paragraph
- change text in the third person;
- one thousand and eighty-eight pregnant women were excluded due to exclusion criteria.;
- 29.9 years (range: 20–44 years). Most (81.5%, n=2558/3139);

Data collection
First paragraph
- change text in the third person;

Third paragraph
- 24h.;

Fourth paragraph
- 24h.

Laboratory methods
Secund paragraph
- 13.000;

Results
First paragraph
- 13.4%, n=422/3139. 27.9±3.5;
- 29.9;
- 27.9±3.5;
- #2=12.1, P=0.001.;
- 13.8% (n=234/1692; #2=0.67, P=0.41).;
- gestations=1.2;
- (72.4%);
- 4.4, 95% CI: 1.8–11.1;
- 3, 95% CI: 1.2–7.4, respectively, P for trend <0.01);
- (1.3%);
- 76.2% (n=32/42).;

Secund paragraph
- (95.5%, n=403/422) of the HPV-positive mothers (13.4%);
- (29.6%, n=125/422), HPV-18 (14.7%, n=62/422), and HPV-58 (14.2%, n=60/422);
- (n=187/422);
- (83.6%);
- 16.3%;
- 46.4% (n=32/69);

Third paragraph
- 23.6% (n=55/233);
- (#2=1.64, P=0.268) and between different delivery types (#2=0.283, P=0.71);
- (56.4%, n=31/55);
- 23.6% (n=55/233.);
- (n=18/26), followed by HPV-11 (n=2/26) and HPV-31 (n=2/26) (Table 2).

Fourth paragraph
- 58.4% (n=36/233) tested neonates were delivered vaginally and
41.6%(n=97/233%) were delivered by cesarean sections (#2=0.119, P>0.005).;
- 23.6% (55/2n=33).;
- 11.2% (n=26/233);

Discussion
First paragraph
- HPV-DNA;
- Results revealed;
- change text in the third person;
- (76.2%);
- no significant influence between delivery type and vertical transmission of HPV;
- change text in the third person;
- HPV-DNA;
- disagreements occurred in 52.7% of HPV genotypes maternal and neonatal;
- change text in the third person;

Second paragraph
- 81.5%;
- change text in the third person;

Third paragraph
- change text in the third person;
- (k=0.82);

Fourth paragraph
- change text in the third person;
- (13.4%) similar to that (13.8%) reported-

Figure 1.
- positive mothers (genital samples);
- mother, genital.

Table 1.
Risk factor HPV-DNA+ OR* CI**
(n=422/3139)

<table>
<thead>
<tr>
<th></th>
<th>n⁰</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- (17.8%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- (12%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- (15.4%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- (13.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- (15.30%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Education (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- (17.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- (12.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- (4.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytological result</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- (12.6%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
OR= Odds ratio; **CI= 95% confidence interval

Table 2.

Table 2. Neonatal HPV status among ..... 

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th></th>
<th>Female</th>
<th></th>
<th>Total</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>nº</td>
<td>%</td>
<td>nº</td>
<td>%</td>
<td>nº</td>
<td>%</td>
</tr>
<tr>
<td>HPV-DNA+</td>
<td>12</td>
<td>11.7</td>
<td>23</td>
<td>17.7</td>
<td>35</td>
<td>15</td>
</tr>
<tr>
<td>HPV-DNA-</td>
<td>91</td>
<td>88.3</td>
<td>107</td>
<td>82.3</td>
<td>198</td>
<td>85</td>
</tr>
<tr>
<td>Total</td>
<td>103</td>
<td>100</td>
<td>130</td>
<td>100</td>
<td>233</td>
<td>100</td>
</tr>
</tbody>
</table>

Table 3.

Table 3. Neonatal HPV status by delivery type.

<table>
<thead>
<tr>
<th></th>
<th>Cesarean section</th>
<th>Vaginal delivery</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>nº</td>
<td>%</td>
<td>nº</td>
</tr>
<tr>
<td>HPV-DNA+</td>
<td>16</td>
<td>16.5</td>
<td>19</td>
</tr>
<tr>
<td>HPV-DNA-</td>
<td>81</td>
<td>83.5</td>
<td>117</td>
</tr>
<tr>
<td>Total</td>
<td>97</td>
<td>100</td>
<td>136</td>
</tr>
</tbody>
</table>

Level of interest: An article of importance in its field

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests below:

- I dont have in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this paper, either now or in the future
- I dont hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this paper, either now or in the future
- I dont hold or currently applying for any patents relating to the content of the manuscript
- I dont have received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript
- I don't have any other financial competing interests
- I don't have any non-financial competing interests in relation to this paper